Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-3: Inclisiran and Evolocumab Extension Study
NCT03060577Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Primary completion
- Dec 2021
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 5
01
Overview
A Phase 2 trial of inclisiran in hypercholesterolemia, sponsored by Novartis. Started Apr 2017; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03060577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03060577.